The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

Sponsor
Humanitas Clinical and Research Center
Study ID
NCT06691061
Status
Recruiting
Apply to this trial

Conditions

  • Ulcerative Colitis (Disorder)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vedolizumab — DRUG
    UC patients treated with vedolizumab
  • Ustekinumab - Standard Dosage — DRUG
    UC patients treated with ustekinumab
  • JAK Inhibitor — DRUG
    UC patients treated with JAK inhibitors

Study Details

The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed to at least one anti-TNF-alpha therapy.

Key Dates

Start date
Aug 1, 2023
Status verified
Nov 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
450 participants (estimated)

Primary Outcome Measure

Clinical and endoscopic effectiveness of the three treatments [ Time Frame: 12 months ]

Central Contacts

Related Studies